Tm Bioscience secures multi-year extension to Luminex partnership:
This article was originally published in Clinica
Canada's Tm Bioscience and Austin, Texas-based Luminex have extended an existing licensing agreement, which gives the former company rights to sell DNA-based molecular tests used on Luminex' xMAP instrument. The renewed multi-year contract will also give Tm Bioscience distribution rights to Luminex's new LX200 system. Tm Bioscience, which develops genetic tests based on its Tag-It universal array technology, and Luminex, which specialises in bead-based bioassay multiplexing, formed their partnership in 2001.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.